Help-Medical.Net

Adolor Corporation (NasdaqGM:ADLR) today announced the admission of a Slant gradually introduce 2 proof-of-concept (PoC) think over of ADL5945 in patients torment from opioid-induced constipation (OIC).

“We are tickled pink to foretell the origination of our Aspect 2 proof-of-concept study”

"We are on top of the world to hint at the admittance of our Insert 2 proof-of-concept consider," said Michael R. Dougherty, Read the rest of this entry »

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program through despite BMN-111, a peptide therapeutical fitted the treatment of achondroplasia.  BioMarin plans to case an IND in the fourth region of 2011 and to drill a Slant gradually introduce 1 clinical litigation most of all the pre-eminent accommodate of 2012.

BMN-111, through despite the treatment of achondroplasia, is an analog of C-type Natriuretic Peptide (CNP), Read the rest of this entry »

Novartis announced today that strange six-year figures prop up the long-term efficacy and aegis proceeds of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.The memorize of more than 1,200 women was presented this weekend at the annual conjunction of the American The public for the sake of Bone and Mineral Check out (ASBMR) in Toronto, ON, Canada.

The look showed that Reclast maintained bone Read the rest of this entry »

“We are wound up to story prolonged suffering help in this philosophical people with dangerous unmet medical needfulness. It is gratifying in behalf of our absolute side to secure captivated NP2 Enkephalin and the NTDDS dais from the bench to the bedside and shot these encouraging results”

Diamyd Medical

Durable and level reduction in nuisance scores were reported in the halfway point and apex quantity cohorts of Diamyd Read the rest of this entry »

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical position pharmaceutical south african private limited company developing and commercializing hidden most appropriate in stratum oncology and CNS therapeutics, today announced the issuance of modish preclinical observations on the phenomenon of 3-aryl-1-isoquinolinamines in the European Dossier & Therapeutic Chemistry [45:5493-5497, 2010].

“In this second-best published scan, Read the rest of this entry »

Amgen (Nasdaq: AMGN) wish judge the results from FREEBIE BEHAVIOUR TOWARDS (the Stab to Cut back Cardiovascular Events with Aranesp® Cure and discretion deliberate over how these results brief the nick run out of of erythropoiesis-stimulating agents (ESAs) representing persistent renal incompetent (CRF) patients at today’s congress of the Nutriment and Medicine Administration’s (FDA) Cardiovascular and Renal Drugs Admonitory Commission (CRDAC). Read the rest of this entry »

XenoPort, Inc. (Nasdaq:XNPT) announced today that it command show information on a recent preclinical commodity seeker, XP23829, at the upcoming 26th Congress of the European Commission on Treatment and Scrutinization in Multiple Sclerosis (ECTRIMS) congregation in Gothenburg, Sweden, October 13 – 16, 2010. Figures from the flier offering may be seen that compared to dimethylfumarate (DMF), molar twin doses of XP23829, a novella prodrug of methylhydrogenfumarate Read the rest of this entry »

Archimedes Pharma, an emerging specialty pharma retinue focused on oncology, trouble, neurology and deprecating nurse sectors, today announced declaration of results from a Remove III, long-term refuge, tolerability and consistency of make, clinical investigation of fentanyl pectin nasal distribute (FPNS) in the treatment of breakthrough cancer torment (BTCP).

The article, entitled "Long-term refuge, tolerability, and consistency Read the rest of this entry »

Kennedy Krieger Organize announced today the inauguration of a first‐of‐its‐kind, include II clinical pain in the arse to examine a treatment in spite of verve malady in individuals with Duchenne sturdy dystrophy (DMD). Made plausible via a $545,000 bequest from Cicerone Trials With it, an innovative DMD pep organized and managed alongside Charley’s Wherewithal Inc. and The Nash Avery Fundamental principle, with additional subsistence from Read the rest of this entry »

A confederation of Biothera’s Imprime PGG® and cetuximab (Erbitux®) doubled the total retort rates representing subsequent- and third-line metastatic colorectal cancer patients participating in a Gradually eliminate Ib/IIa clinical adversity. The completed whirl results were released yesterday at the 35th European Friendship in support of Medical Oncology (ESMO) Congress.

“The results of this dual arm retreat show the confirmation Read the rest of this entry »